Generation of a non-small cell lung cancer transcriptome microarray

A. Tanney; G.R. Oliver; V. Farztdinov; Richard Kennedy; J.M. Mulligan; C.E. Fulton; S.M. Farragher; J.K. Field; Patrick Johnston; Paul Harkin; V. Proutski; K.A. Mulligan

doi:10.1186/1755-8794-1-20

Generation of a non-small cell lung cancer transcriptome microarray

A. Tanney, G.R. Oliver, V. Farztdinov, Richard Kennedy, J.M. Mulligan, C.E. Fulton, S.M. Farragher, J.K. Field, Patrick Johnston, Paul Harkin, V. Proutski, K.A. Mulligan

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. At present no reliable biomarkers are available to guide the management of this condition. Microarray technology may allow appropriate biomarkers to be identified but present platforms are lacking disease focus and are thus likely to miss potentially vital information contained in patient tissue samples.

Original language	English
Pages (from-to)	20-25
Number of pages	6
Journal	BMC Medical Genomics
Volume	1
DOIs	https://doi.org/10.1186/1755-8794-1-20
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1755-8794-1-20

Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation
Richard Kennedy (Participant), Denis Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant) & Daniel Longley (Participant)
Impact: Health Impact, Quality of Life Impact

Cite this

@article{4fb71fb8e4b6448ca4fc94e85e40d893,

title = "Generation of a non-small cell lung cancer transcriptome microarray",

abstract = "Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. At present no reliable biomarkers are available to guide the management of this condition. Microarray technology may allow appropriate biomarkers to be identified but present platforms are lacking disease focus and are thus likely to miss potentially vital information contained in patient tissue samples.",

author = "A. Tanney and G.R. Oliver and V. Farztdinov and Richard Kennedy and J.M. Mulligan and C.E. Fulton and S.M. Farragher and J.K. Field and Patrick Johnston and Paul Harkin and V. Proutski and K.A. Mulligan",

year = "2008",

doi = "10.1186/1755-8794-1-20",

language = "English",

volume = "1",

pages = "20--25",

journal = "BMC Medical Genomics",

issn = "1755-8794",

publisher = "BioMed Central",

}

Generation of a non-small cell lung cancer transcriptome microarray. / Tanney, A.; Oliver, G.R.; Farztdinov, V.; Kennedy, Richard; Mulligan, J.M.; Fulton, C.E.; Farragher, S.M.; Field, J.K.; Johnston, Patrick; Harkin, Paul; Proutski, V.; Mulligan, K.A.

In: BMC Medical Genomics, Vol. 1, 2008, p. 20-25.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Generation of a non-small cell lung cancer transcriptome microarray

AU - Tanney, A.

AU - Oliver, G.R.

AU - Farztdinov, V.

AU - Kennedy, Richard

AU - Mulligan, J.M.

AU - Fulton, C.E.

AU - Farragher, S.M.

AU - Field, J.K.

AU - Johnston, Patrick

AU - Harkin, Paul

AU - Proutski, V.

AU - Mulligan, K.A.

PY - 2008

Y1 - 2008

N2 - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. At present no reliable biomarkers are available to guide the management of this condition. Microarray technology may allow appropriate biomarkers to be identified but present platforms are lacking disease focus and are thus likely to miss potentially vital information contained in patient tissue samples.

AB - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. At present no reliable biomarkers are available to guide the management of this condition. Microarray technology may allow appropriate biomarkers to be identified but present platforms are lacking disease focus and are thus likely to miss potentially vital information contained in patient tissue samples.

U2 - 10.1186/1755-8794-1-20

DO - 10.1186/1755-8794-1-20

M3 - Article

C2 - 18513400

VL - 1

SP - 20

EP - 25

JO - BMC Medical Genomics

JF - BMC Medical Genomics

SN - 1755-8794

ER -

Generation of a non-small cell lung cancer transcriptome microarray

Abstract

UN SDGs

Access to Document

Fingerprint

Impacts

Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

Cite this